Walgreens (NYSE:WAG)(Nasdaq:WAG) announces the launch of the 2014 Walgreens Way to Well Health Tour with AARP. For six years, Walgreens and AARP have conducted the community outreach program dedicated to providing free preventive and early detection health services to communities across the country. Now through December, Walgreens will use the tour to provide free health tests, assessments, education and consulting services with a renewed commitment to the everyday health of Americans nationwide.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7158751-walgreens-2014-way-to-well-health-tour-aarp
This toothbrush rap music or call it hip hop music from http://ToothBrushIt.com is very nice. It advises people to regularly brush their teeth and to buy their toothbrush from ToothBrushIt.com website, in a hillarious way. Check it out!!!
The Breakthrough: Avon delivers game-changing innovation with Mega Effects Mascara, unveiling a completely new approach to mascara application. Six years in the making, this volumizing mascara is the result of feedback from over 2,000 women and 5,000 hours of science.
The Wonderbrush: Mega Effects Mascara replaces the standard wand with an innovative new multi-dimensional brush that lifts top and bottom lashes from root to tip in a whole new way. The first-ever brush of its kind, the Wonderbrush fits the curve of your eyes and can be used at 12 different angles for a corner to corner lash transformation. The bigger bristle area combs through lashes easily for phenomenal clump-free volume, putting 40 percent more mascara to lash*.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62677-avon-mega-effects-volumizing-mascara-makeup
Horyou.com, the action-oriented social network for the common good announces its international public beta release. In its first stage, the platform is available to all Internet users in four languages: English, Spanish, Portuguese and French.
Horyou is an international company that promotes a humanistic approach to technology through an online platform that encourages its members to dream, inspire and act.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64173-horyou-new-social-network-public-beta
Most people are deficient in vitamin D3. You can supplement with 2000, 5000, or 10,000 IU of vitamin D3 but that may not be enough. The only way to tell if your blood has an adequate amount of D3 is to have a blood test for D3 and have your doctor examine the results.
Get Back - check out Ruby Rose singing 'One Way Or Another' for the launch of JAG Bombshells, along with Jay Lyons. Like Ruby's jeans? Grab the Bombshells here: http://www.jag.com.au/the-look/womens-denim/ #JAGGETBACK LINKS: http://shop.jag.com.au/ http://www.facebook.com/JAGAustralia https://twitter.com/jag_aus/ http://instagram.com/jag_aus/
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
